Tissue and cell type-associated traits map for all cell types in [CordBlood] . Due to the large number of UKBB panel traits, this figure shows the non-UKBB traits with a CSEA p (chi2) < 1e-05 as default, and users can change it to 1e-04, 1e-06. For each cell type and trait association pair (shown as an edge in the figure), there may be multiple trait-associated-gene (TAG) sets, each defined at a different threshold. The pair with the minimum p-value is shown in the figure, with the p-value showing along each edge. The number of edges in the figure is thus less than (or equal to) the number of entries in the table below. Users could further select to only show the association for those ‘tissue-specfic cell types’ defined from ontology analysis.
Table. List of Tissue-cell type associated traits pairs for [CordBlood]. If the network above is too complicated, the users could obtain the association information from the table at bottom. Because each trait might have multiple TAG sets defined at different thresholds, multiple rows for each cell type and trait pair with different "TAG Set Threshold" and " CSEA p (chi2)" (the last two columns). Users could identify the most significant association by sorting “CSAE p (chi2)” column.
Cell type | Trait name | Trait full name | Panel | Author | Year | Cases* | Controls | TAG Set Threshold |
CSEA p (chi2) |
---|---|---|---|---|---|---|---|---|---|
CB CD34+ | 2 Hour Glucose | 2-Hour Glucose | ETC | Saxena | 2010 | NA | 15234 | 1.00e-3 | 4.37e-2 |
Erythroid cell | ADHD | Attention Deficit Hyperactivity Disorder | ETC | Demontis | 2017 | 19099 | 34194 | 1.00e-3 | 4.90e-2 |
Monocyte | Aggression | Aggression | MTC | Pappa | 2015 | NA | 15668 | 5.00e-2 | 3.92e-2 |
Monocyte | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 5.00e-2 | 1.53e-2 |
Monocyte | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 1.26e-2 |
Monocyte | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 2.12e-2 |
Monocyte | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 3.17e-3 |
Monocyte | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 8.04e-4 |
Antigen presenting cell (RPS high) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-2 | 3.59e-3 |
Antigen presenting cell (RPS high) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 2.73e-3 |
Antigen presenting cell (RPS high) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 3.17e-3 |
Antigen presenting cell (RPS high) | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 4.22e-3 |
Dendritic cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-3 | 3.30e-2 |
Dendritic cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-4 | 7.46e-4 |
Dendritic cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 1.26e-4 |
T cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 1.80e-2 |
B cell | Allergies | Allergies | MTC | Ferreira | 2017 | NA | 180709 | 1.00e-5 | 1.89e-3 |
Monocyte | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 5.00e-2 | 7.68e-4 |
Monocyte | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-2 | 1.84e-2 |
Monocyte | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-3 | 3.25e-3 |
Monocyte | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-4 | 1.00e-3 |
Monocyte | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-5 | 8.93e-3 |
Dendritic cell | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-4 | 1.79e-2 |
Dendritic cell | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-5 | 2.42e-2 |
B cell | Alzheimers | Alzheimer's Disease | MTC | Jansen | 2019 | 71880 | 383378 | 1.00e-5 | 2.42e-2 |
Monocyte | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 5.00e-2 | 1.54e-2 |
Monocyte | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-2 | 8.35e-3 |
Monocyte | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-3 | 2.80e-3 |
Monocyte | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 1.22e-2 |
Monocyte | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-5 | 6.27e-4 |
Dendritic cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 1.22e-2 |
B cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-4 | 1.22e-2 |
B cell | Alzheimers | Alzheimer's Disease | ETC | Lambert | 2013 | 17008 | 37154 | 1.00e-5 | 3.45e-2 |
Dendritic cell | Anorexia Nervosa | Anorexia Nervosa | MTC | Duncan | 2017 | 3495 | 10982 | 1.00e-2 | 2.02e-2 |
Antigen presenting cell (RPS high) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 3.63e-2 |
Antigen presenting cell (RPS high) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 6.08e-3 |
Antigen presenting cell (RPS high) | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 1.22e-2 |
Dendritic cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-3 | 8.70e-3 |
Dendritic cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 6.08e-3 |
Dendritic cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 3.15e-4 |
Monocyte | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-4 | 3.71e-2 |
Monocyte | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 3.33e-2 |
B cell | Asthma | Asthma | MTC | Demenais | 2017 | 19954 | 107715 | 1.00e-5 | 1.22e-2 |
Dendritic cell | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-3 | 8.61e-3 |
Dendritic cell | Asthma | Asthma | MTC | Moffatt | 2010 | 10365 | 16110 | 1.00e-4 | 1.56e-2 |
CB CD34+ | BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-4 | 4.91e-2 |
Erythroid cell | BIP | Bipolar Disorder | MTC | Psychiatric-Genomics-Consortium | 2012 | 7481 | 9250 | 1.00e-4 | 1.17e-2 |
Erythroid progenitor cell (RP high) | Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 5.00e-2 | 2.76e-2 |
Erythroid progenitor cell (RP high) | Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 1.00e-2 | 4.69e-3 |
Erythroid progenitor cell (RP high) | Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 1.00e-3 | 4.80e-2 |
Dendritic cell | Birth Length | Birth Length | MTC | van-der-Valk | 2014 | NA | 28238 | 5.00e-2 | 4.12e-2 |
CB CD34+ | BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-3 | 1.03e-2 |
CB CD34+ | BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-4 | 5.94e-3 |
Erythroid progenitor cell (RP high) | BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-3 | 2.89e-2 |
Erythroid progenitor cell (RP high) | BMI | Body Mass Index | MTC | Wood | 2016 | 29925 | 89763 | 1.00e-2 | 3.59e-2 |
Erythroid cell | BMI | Body Mass Index | MTC | Yang | 2012 | NA | 133154 | 5.00e-2 | 2.64e-3 |
Neutrophil | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 1.86e-2 |
Neutrophil | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-3 | 4.62e-2 |
B cell | Bone Mineral Density | Bone Mineral Density | MTC | Styrkarsdottir | 2008 | 4657 | 207514 | 1.00e-2 | 1.01e-2 |
Erythroid progenitor cell (RP high) | Cerebral White Matter Hyperintensity | Cerebral White Matter Hyperintensity | MTC | Traylor | 2016 | NA | 3670 | 5.00e-2 | 3.81e-2 |
Monocyte | Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 5.00e-2 | 5.64e-3 |
Neutrophil | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 4.70e-2 |
B cell | Cognitive Performance | Cognitive Performance | MTC | Rietveld | 2014 | NA | 106736 | 1.00e-2 | 4.70e-2 |
Monocyte | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 5.00e-2 | 2.84e-2 |
Monocyte | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 7.24e-3 |
Monocyte | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 4.48e-2 |
Monocyte | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 1.85e-2 |
Monocyte | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 2.96e-2 |
Dendritic cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-2 | 1.13e-2 |
Dendritic cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-3 | 2.76e-2 |
Dendritic cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 9.40e-3 |
Dendritic cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 1.41e-2 |
B cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-4 | 9.40e-3 |
B cell | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 6.31e-3 |
Antigen presenting cell (RPS high) | CD | Crohn's disease | MTC | Franke | 2010 | 6333 | 15056 | 1.00e-5 | 2.96e-2 |
CB CD34+ | CD | Crohn's disease | MTC | Lee | 2017 | 1762 | 972 | 1.00e-4 | 1.89e-2 |
Dendritic cell | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-3 | 1.62e-2 |
Dendritic cell | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 4.62e-2 |
Dendritic cell | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-5 | 1.17e-2 |
B cell | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 1.67e-2 |
B cell | Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-5 | 1.17e-2 |
Monocyte | Depressive Symptoms | Depressive Symptoms | ETC | Okbay | 2016 | 122210 | 58835 | 5.00e-2 | 2.47e-2 |
Erythroid progenitor cell (RP high) | Extraversion | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 4.40e-2 |
Erythroid progenitor cell (RP high) | Extraversion | Extraversion | MTC | van-den-Berg | 2016 | NA | 63030 | 1.00e-2 | 4.40e-2 |
Antigen presenting cell (RPS high) | Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 5.00e-2 | 3.33e-2 |
Neutrophil | Gait Speed | Gait Speed | MTC | Ben-Avraham | 2017 | NA | 31478 | 1.00e-2 | 3.59e-2 |
Antigen presenting cell (RPS high) | Head Circumference | Head Circumference | MTC | Taal | 2012 | NA | 10768 | 1.00e-2 | 2.80e-2 |
Monocyte | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 7.15e-3 |
Monocyte | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 2.63e-2 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 1.50e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 2.63e-2 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-3 | 8.22e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-4 | 9.74e-4 |
T cell | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-2 | 2.63e-2 |
Antigen presenting cell (RPS high) | Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 1.00e-3 | 2.25e-2 |
Erythroid progenitor cell (RP high) | Insomnia | Insomnia | MTC | Hammerschlag | 2017 | 12863 | 40776 | 5.00e-2 | 3.80e-2 |
Erythroid progenitor cell (RP high) | Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 5.00e-2 | 2.87e-2 |
Erythroid progenitor cell (RP high) | Intelligence | Intelligence | MTC | Sniekers | 2017 | NA | 78308 | 1.00e-2 | 2.62e-2 |
Neutrophil (RPS high) | Male Pattern Baldness | Male Pattern Baldness | MTC | Hagenaars | 2017 | NA | 52874 | 5.00e-2 | 1.65e-2 |
Monocyte | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 1.15e-2 |
Monocyte | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 1.14e-2 |
Monocyte | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 1.87e-5 |
Monocyte | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 1.51e-4 |
Monocyte | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 1.53e-4 |
Dendritic cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 6.82e-3 |
Dendritic cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 2.80e-4 |
Dendritic cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 1.87e-5 |
Dendritic cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 2.78e-5 |
Dendritic cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 3.53e-6 |
B cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 5.00e-2 | 3.92e-3 |
B cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 1.14e-2 |
B cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 1.87e-5 |
B cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 4.57e-6 |
B cell | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-5 | 2.47e-5 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-2 | 4.90e-2 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-3 | 4.62e-2 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | MTC | Hafler | 2007 | 931 | 2431 | 1.00e-4 | 1.17e-2 |
Monocyte | Neuroticism | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.29e-2 |
B cell | Neuroticism | Neuroticism | MTC | Luciano | 2017 | NA | 329821 | 1.00e-4 | 2.55e-2 |
Erythroid progenitor cell (RP high) | Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | ETC | Arnold | 2017 | 2688 | 7037 | 5.00e-2 | 2.24e-2 |
B cell | Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | ETC | Arnold | 2017 | 2688 | 7037 | 5.00e-2 | 3.47e-2 |
Neutrophil (RPS high) | Obsessive Compulsive Disorder | Obsessive Compulsive Disorder | ETC | Arnold | 2017 | 2688 | 7037 | 1.00e-2 | 2.00e-2 |
Monocyte | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 5.00e-2 | 2.01e-2 |
Monocyte | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-3 | 4.30e-2 |
Monocyte | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 2.98e-2 |
Erythroid cell | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-2 | 1.74e-2 |
Dendritic cell | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 2.98e-2 |
B cell | Parkinsons | Parkinson's Disease | MTC | Pankratz | 2012 | 4238 | 4239 | 1.00e-4 | 2.98e-2 |
Monocyte | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 3.96e-2 |
Monocyte | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 3.11e-4 |
Monocyte | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 6.79e-5 |
Monocyte | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 8.99e-4 |
Monocyte | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 1.93e-3 |
Antigen presenting cell (RPS high) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 1.92e-2 |
Antigen presenting cell (RPS high) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 5.97e-3 |
Antigen presenting cell (RPS high) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 1.37e-2 |
Antigen presenting cell (RPS high) | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 1.24e-2 |
Dendritic cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 3.96e-2 |
Dendritic cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 2.47e-2 |
Dendritic cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 1.25e-2 |
Dendritic cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 8.99e-4 |
Dendritic cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 2.27e-4 |
B cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-2 | 1.46e-2 |
B cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-3 | 1.84e-4 |
B cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-4 | 1.06e-4 |
B cell | Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 1.00e-5 | 2.27e-4 |
Neutrophil (RPS high) | Prostate Cancer | Prostate Cancer | MTC | Yeager | 2007 | 1172 | 1157 | 1.00e-2 | 1.08e-2 |
Monocyte | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 5.00e-2 | 4.67e-3 |
Monocyte | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 4.76e-4 |
Monocyte | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 1.61e-3 |
Monocyte | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 6.68e-4 |
Monocyte | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 1.16e-3 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 5.00e-2 | 4.67e-3 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 1.64e-3 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 2.34e-4 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 3.68e-5 |
Erythroid cell | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 6.49e-6 |
Erythroid progenitor cell (RP high) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 5.00e-2 | 3.40e-2 |
Erythroid progenitor cell (RP high) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-2 | 4.39e-2 |
Erythroid progenitor cell (RP high) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-3 | 3.48e-2 |
Erythroid progenitor cell (RP high) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-4 | 3.02e-3 |
Erythroid progenitor cell (RP high) | Red Blood Cell Distribution Width | Red Blood Cell Distribution Width | MTC | Pilling | 2017 | NA | 116666 | 1.00e-5 | 6.55e-4 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 9.78e-3 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 4.70e-3 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 1.11e-2 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 3.78e-2 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 5.00e-2 | 3.22e-2 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 2.46e-3 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 8.28e-4 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 2.63e-5 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 2.53e-6 |
Dendritic cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-2 | 2.63e-2 |
Dendritic cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 3.11e-4 |
Dendritic cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 7.06e-6 |
Dendritic cell | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 1.07e-5 |
Monocyte | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-3 | 2.33e-2 |
Monocyte | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-4 | 2.61e-3 |
Monocyte | Rheumatoid Arthritis | Rheumatoid Arthritis | ETC | Stahl | 2010 | 5539 | 20169 | 1.00e-5 | 1.66e-3 |
Dendritic cell | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-2 | 3.50e-2 |
Dendritic cell | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 3.24e-3 |
Dendritic cell | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-4 | 4.28e-2 |
Dendritic cell | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-5 | 6.36e-3 |
Monocyte | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 3.00e-2 |
Monocyte | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-4 | 1.76e-2 |
Monocyte | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-5 | 6.36e-3 |
B cell | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-3 | 7.20e-3 |
B cell | Self Rated Health | Self Rated Health | MTC | Harris | 2016 | NA | 111749 | 1.00e-5 | 2.10e-2 |
Monocyte | Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-2 | 1.52e-2 |
Erythroid progenitor cell (RP high) | Subjective Well Being | Subjective Well Being | ETC | Okbay | 2016 | NA | 298420 | 1.00e-4 | 2.22e-2 |
T cell | Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 1.00e-2 | 2.73e-2 |
Erythroid cell | Type 2 Diabetes | Type 2 Diabetes | ETC | Morris | 2012 | 12171 | 56862 | 1.00e-3 | 3.80e-2 |
Monocyte | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 5.00e-2 | 2.54e-5 |
Monocyte | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-2 | 1.60e-4 |
Monocyte | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 1.34e-5 |
Monocyte | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 4.59e-6 |
Monocyte | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 2.73e-4 |
Dendritic cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 5.00e-2 | 2.50e-2 |
Dendritic cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-2 | 9.74e-4 |
Dendritic cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 5.14e-6 |
Dendritic cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 1.39e-6 |
Dendritic cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 3.66e-7 |
B cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-3 | 2.55e-2 |
B cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-4 | 2.12e-3 |
B cell | UC | Ulcerative Colitis | MTC | Anderson | 2011 | 6687 | 19718 | 1.00e-5 | 8.42e-4 |
Dendritic cell | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-4 | 2.03e-2 |
B cell | Waist Hip Ratio Adjusted For BMI | Waist Hip Ratio Adjusted For BMI | MTC | Heid | 2010 | NA | 77167 | 1.00e-4 | 2.03e-2 |
Antigen presenting cell (RPS high) | Warfarin maintenance dose | Warfarin maintenance dose | MTC | Cooper | 2008 | NA | 181 | 1.00e-3 | 2.58e-2 |
Erythroid progenitor cell (RP high) | Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 5.27e-3 |
Erythroid cell | Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 1.00e-2 | 2.83e-2 |
Erythroid progenitor cell (RP high) | Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-2 | 4.11e-2 |
Erythroid progenitor cell (RP high) | Alcohol Consumption | Alcohol Consumption All Continuous | MTC | Schumann | 2016 | NA | 70460 | 1.00e-3 | 3.59e-2 |
Neutrophil | Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 8.08e-3 |
T cell | Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 1.00e-2 | 4.58e-2 |
Erythroid cell | Alcohol Consumption | Alcohol Consumption Men Dichotomous | MTC | Schumann | 2016 | NA | 26991 | 5.00e-2 | 3.05e-3 |
Erythroid progenitor cell (RP high) | Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 5.00e-2 | 3.25e-2 |
Erythroid progenitor cell (RP high) | Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-2 | 1.29e-3 |
Antigen presenting cell (RPS high) | Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-2 | 2.13e-2 |
Monocyte | Alcohol Consumption | Alcohol Consumption Women Continuous | MTC | Schumann | 2016 | NA | 42900 | 1.00e-3 | 2.30e-2 |
Erythroid progenitor cell (RP high) | Alcohol Consumption | Alcohol Consumption Women Dichotomous | MTC | Schumann | 2016 | NA | 47720 | 5.00e-2 | 2.84e-2 |
Monocyte | Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 5.35e-3 |
B cell | Alzheimers Protein Levels | Phosphorylated Tau Position 181 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-3 | 3.87e-2 |
B cell | Anthropometric Extremes | Extreme BMI | MTC | Berndt | 2013 | 7962 | 8106 | 1.00e-3 | 2.10e-2 |
CB CD34+ | Anthropometric Extremes | Obesity Class 1 | MTC | Berndt | 2013 | 32858 | 65840 | 1.00e-4 | 1.91e-2 |
CB CD34+ | Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 1.00e-3 | 4.53e-2 |
Neutrophil (RPS high) | Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 5.00e-2 | 2.48e-2 |
Erythroid progenitor cell (RP high) | Anthropometric Extremes | Obesity Class 3 | MTC | Berndt | 2013 | 2896 | 65840 | 5.00e-2 | 2.48e-2 |
Erythroid progenitor cell (RP high) | Anthropometric Extremes | Overweight | MTC | Berndt | 2013 | 93015 | 65840 | 1.00e-4 | 3.59e-2 |
CB CD34+ | Anthropometrics Sex Stratified | Body Mass Index Men | MTC | Randall | 2013 | 60586 | 60856 | 1.00e-4 | 8.47e-3 |
Antigen presenting cell (RPS high) | Anthropometrics Sex Stratified | Hip Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34942 | 1.00e-4 | 2.22e-2 |
Monocyte | Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 5.00e-2 | 8.95e-3 |
Monocyte | Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 1.00e-2 | 3.87e-2 |
Neutrophil | Anthropometrics Sex Stratified | Hip Circumference Men | MTC | Randall | 2013 | NA | 34942 | 1.00e-3 | 4.37e-2 |
Antigen presenting cell (RPS high) | Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 2.82e-2 |
Erythroid progenitor cell (RP high) | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 4.27e-2 |
CB CD34+ | Anthropometrics Sex Stratified | Waist Circumference Adjusted For BMI Women | MTC | Randall | 2013 | NA | 45192 | 1.00e-2 | 4.22e-2 |
Neutrophil | Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 5.00e-2 | 1.90e-2 |
Erythroid progenitor cell (RP high) | Anthropometrics Sex Stratified | Waist Circumference Men | MTC | Randall | 2013 | NA | 36231 | 1.00e-3 | 2.30e-2 |
Dendritic cell | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 3.13e-2 |
B cell | Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 4.99e-2 |
Dendritic cell | Anthropometrics Sex Stratified | Waist Hip Ratio Men | MTC | Randall | 2013 | NA | 34629 | 5.00e-2 | 2.65e-2 |
CB CD34+ | Anthropometrics Sex Stratified | Weight Men | MTC | Randall | 2013 | NA | 60856 | 1.00e-4 | 3.45e-2 |
Antigen presenting cell (RPS high) | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-4 | 6.27e-4 |
Antigen presenting cell (RPS high) | Anthropometrics Sex Stratified | Weight Women | MTC | Randall | 2013 | NA | 73137 | 1.00e-5 | 2.22e-2 |
Antigen presenting cell (RPS high) | Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 5.00e-2 | 2.55e-2 |
Erythroid cell | Anxiety | Anxiety Continuous | ETC | Otowa | 2016 | NA | 18186 | 5.00e-2 | 4.13e-2 |
Erythroid cell | Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 5.00e-2 | 1.18e-2 |
Antigen presenting cell (RPS high) | Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-2 | 4.38e-2 |
T cell | Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-2 | 4.38e-2 |
Neutrophil | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 2.74e-2 |
Neutrophil | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 1.00e-3 | 3.41e-2 |
Erythroid cell | Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 4.16e-2 |
Neutrophil | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.70e-2 |
Neutrophil | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.48e-2 |
Monocyte | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.17e-2 |
Monocyte | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.75e-2 |
Antigen presenting cell (RPS high) | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.17e-2 |
Antigen presenting cell (RPS high) | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.48e-2 |
Antigen presenting cell (RPS high) | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 2.29e-2 |
CB CD34+ | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 6.11e-3 |
CB CD34+ | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 4.64e-4 |
CB CD34+ | Blood Cells | Lymphocyte Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-4 | 6.21e-3 |
Neutrophil (RPS high) | Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.62e-2 |
Erythroid progenitor cell (RP high) | Blood Cells | Mean Corpuscular Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.07e-2 |
Monocyte | Blood Cells | Mean Corpuscular Hemoglobin Concentration | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.71e-2 |
Erythroid cell | Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.65e-3 |
Erythroid cell | Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.69e-2 |
Erythroid progenitor cell (RP high) | Blood Cells | Mean Erythrocyte Cell Volume | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.91e-3 |
Monocyte | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.29e-2 |
Monocyte | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.48e-2 |
Dendritic cell | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 8.39e-3 |
Antigen presenting cell (RPS high) | Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.42e-3 |
Neutrophil (RPS high) | Blood Cells | Platelet Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 2.58e-2 |
Antigen presenting cell (RPS high) | Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.15e-2 |
Monocyte | Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 1.79e-2 |
Dendritic cell | Blood Cells | Red Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 3.98e-2 |
Antigen presenting cell (RPS high) | Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.13e-4 |
Antigen presenting cell (RPS high) | Blood Cells | Total Blood Hemoglobin | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.43e-2 |
Monocyte | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 4.44e-2 |
Monocyte | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-2 | 2.88e-3 |
Monocyte | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 3.45e-2 |
B cell | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 2.91e-2 |
B cell | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 1.17e-2 |
Antigen presenting cell (RPS high) | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 3.45e-2 |
CB CD34+ | Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 1.00e-3 | 3.45e-2 |
B cell | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-2 | 3.16e-2 |
Monocyte | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-3 | 3.32e-2 |
Antigen presenting cell (RPS high) | Blood Lipids | Low Density Lipoprotein | ETC | Teslovich | 2010 | NA | 95454 | 1.00e-4 | 2.96e-2 |
Monocyte | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 5.00e-2 | 2.71e-2 |
Monocyte | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 4.29e-2 |
Dendritic cell | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-3 | 6.03e-3 |
Dendritic cell | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 4.29e-2 |
CB CD34+ | Blood Lipids | Total Cholesterol | ETC | Teslovich | 2010 | NA | 100184 | 1.00e-4 | 4.29e-2 |
Monocyte | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 5.00e-2 | 7.36e-3 |
Monocyte | Blood Lipids | Triglycerides | ETC | Teslovich | 2010 | NA | 96598 | 1.00e-2 | 8.34e-3 |
B cell | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 3.93e-2 |
Monocyte | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 7.88e-3 |
Monocyte | Blood Lipids | High Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 4.45e-2 |
B cell | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 4.30e-2 |
B cell | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 2.77e-2 |
B cell | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 3.68e-2 |
Monocyte | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 2.77e-2 |
Monocyte | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 9.33e-3 |
Monocyte | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 1.34e-2 |
Antigen presenting cell (RPS high) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 2.77e-2 |
Antigen presenting cell (RPS high) | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 1.91e-2 |
Dendritic cell | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 1.52e-2 |
Dendritic cell | Blood Lipids | Low Density Lipoprotein GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 3.68e-2 |
Monocyte | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 3.74e-3 |
Monocyte | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 2.25e-2 |
Monocyte | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 2.95e-2 |
Monocyte | Blood Lipids | Total Cholesterol GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-5 | 3.32e-2 |
Monocyte | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 5.00e-2 | 1.00e-2 |
Monocyte | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-2 | 5.42e-3 |
Monocyte | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-3 | 3.32e-2 |
Monocyte | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 4.97e-2 |
CB CD34+ | Blood Lipids | Triglycerides GWAS and Metabochip | MTC | Willer | 2013 | NA | 94595 | 1.00e-4 | 4.97e-2 |
Neutrophil (RPS high) | BMI Age Stratified | BMI Men Age Over 50 | MTC | Winkler | 2015 | NA | 90988 | 5.00e-2 | 1.88e-2 |
CB CD34+ | BMI Age Stratified | BMI Men Age Under 50 | MTC | Winkler | 2015 | NA | 51625 | 1.00e-4 | 7.13e-3 |
CB CD34+ | BMI Age Stratified | BMI Women Age Under 50 | MTC | Winkler | 2015 | NA | 60654 | 1.00e-4 | 3.16e-2 |
CB CD34+ | BMI Age Stratified | BMI Women Age Under 50 | MTC | Winkler | 2015 | NA | 60654 | 1.00e-5 | 2.22e-2 |
Monocyte | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 1.00e-3 | 3.87e-2 |
Erythroid progenitor cell (RP high) | BMI Age Stratified | Waist Hip Ratio Adjusted For BMI Men Under 50 | MTC | Winkler | 2015 | NA | 43776 | 1.00e-3 | 3.87e-2 |
CB CD34+ | BMI | BMI European Men | MTC | Locke | 2015 | NA | 104666 | 1.00e-5 | 2.90e-2 |
Neutrophil (RPS high) | BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.30e-2 |
CB CD34+ | BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 1.53e-2 |
CB CD34+ | BMI Physical Activity Interaction | BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 3.59e-2 |
CB CD34+ | BMI Physical Activity Interaction | BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 3.41e-2 |
CB CD34+ | BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 1.22e-2 |
CB CD34+ | BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 3.22e-3 |
B cell | BMI Physical Activity Interaction | BMI Adjusted For Physical Activity European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 2.88e-3 |
Antigen presenting cell (RPS high) | BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.59e-2 |
Monocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.07e-2 |
Monocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 1.67e-2 |
Monocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 6.99e-3 |
Monocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.41e-2 |
Neutrophil (RPS high) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Active European Women | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 3.23e-2 |
Erythroid cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.65e-2 |
Erythroid progenitor cell (RP high) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.24e-2 |
Erythroid progenitor cell (RP high) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 2.38e-2 |
Monocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.09e-2 |
Erythroid progenitor cell (RP high) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.78e-2 |
Monocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.46e-2 |
Monocyte | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 1.91e-2 |
Antigen presenting cell (RPS high) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.65e-2 |
Erythroid cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.82e-2 |
Neutrophil | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.87e-2 |
Erythroid cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.03e-3 |
Erythroid cell | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 4.92e-2 |
Erythroid progenitor cell (RP high) | BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.87e-2 |
CB CD34+ | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 4.91e-2 |
CB CD34+ | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 1.90e-2 |
CB CD34+ | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 2.62e-2 |
Neutrophil | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 1.24e-2 |
Neutrophil | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Adjusted For Physical Activity European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.12e-2 |
Erythroid progenitor cell (RP high) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 2.67e-2 |
Erythroid cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 2.42e-2 |
Dendritic cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.77e-2 |
Dendritic cell | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.62e-3 |
Neutrophil | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 3.11e-2 |
Erythroid progenitor cell (RP high) | BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Inactive European Women | MTC | GIANT | 2017 | NA | 132115 | 5.00e-2 | 4.46e-2 |
Neutrophil (RPS high) | BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.69e-2 |
CB CD34+ | BMI Smoking Adjusted | BMI Smoking Adjusted European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.69e-2 |
Erythroid progenitor cell (RP high) | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 4.52e-2 |
Erythroid progenitor cell (RP high) | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 3.55e-2 |
Erythroid progenitor cell (RP high) | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.87e-2 |
Dendritic cell | BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 3.15e-2 |
Monocyte | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 1.36e-2 |
Monocyte | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.81e-5 |
Monocyte | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 4.84e-3 |
Monocyte | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.70e-4 |
B cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 4.73e-2 |
B cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 3.81e-2 |
B cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.14e-2 |
Dendritic cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-4 | 3.81e-2 |
Dendritic cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-5 | 2.14e-2 |
Antigen presenting cell (RPS high) | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.34e-2 |
CB CD34+ | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.34e-2 |
B cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Men European | MTC | GIANT | 2017 | NA | 104666 | 1.00e-3 | 4.34e-2 |
Monocyte | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 4.82e-3 |
Monocyte | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 2.40e-3 |
Monocyte | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-5 | 2.58e-2 |
Dendritic cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 3.16e-2 |
B cell | BMI Smoking Adjusted | Waist Hip Ratio Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-4 | 3.16e-2 |
Monocyte | Bone Mineral Density | Femoral Neck Bone Mineral Density Men | MTC | Estrada | 2012 | NA | 32961 | 5.00e-2 | 9.54e-3 |
Erythroid progenitor cell (RP high) | Bone Mineral Density Lifecourse | Total Body Bone Mineral Density Under 15 | MTC | Medina-Gomez | 2018 | NA | 11807 | 1.00e-2 | 2.85e-2 |
Erythroid progenitor cell (RP high) | Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 5.00e-2 | 3.61e-2 |
Erythroid progenitor cell (RP high) | Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 1.00e-2 | 3.14e-3 |
Erythroid cell | Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 1.00e-2 | 3.59e-2 |
Erythroid cell | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 5.00e-2 | 2.92e-2 |
Erythroid progenitor cell (RP high) | Breast Cancer | Breast Cancer | MTC | Milne | 2017 | 14135 | 58126 | 5.00e-2 | 4.82e-2 |
Neutrophil (RPS high) | Cognitive Functions | Reaction Time | MTC | Davies | 2016 | NA | 111483 | 1.00e-4 | 4.80e-2 |
Erythroid cell | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-2 | 3.02e-2 |
Erythroid cell | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-3 | 2.97e-2 |
Erythroid cell | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-4 | 3.55e-3 |
Erythroid progenitor cell (RP high) | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-2 | 1.80e-2 |
Erythroid progenitor cell (RP high) | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-4 | 1.29e-2 |
CB CD34+ | Cognitive Functions | Verbal Numeric Reasoning | MTC | Davies | 2016 | NA | 36035 | 1.00e-4 | 4.09e-2 |
Monocyte | Coronary Artery Disease | Coronary Artery Disease Recessive Model | MTC | Nikpay | 2015 | 42096 | 99121 | 1.00e-2 | 4.53e-2 |
Erythroid cell | Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 1.00e-2 | 3.31e-2 |
Neutrophil | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 3.49e-2 |
Monocyte | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 4.96e-3 |
Monocyte | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-3 | 3.59e-2 |
Erythroid progenitor cell (RP high) | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 1.00e-2 | 2.55e-2 |
Monocyte | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 8.95e-3 |
Erythroid cell | Ectopic Fat Traits | Pericardial Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 3640 | 5.00e-2 | 3.62e-2 |
B cell | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14668 | 1.00e-3 | 3.41e-2 |
Erythroid progenitor cell (RP high) | Ectopic Fat Traits | Ratio Of Visceral To Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7618 | 5.00e-2 | 2.23e-2 |
Neutrophil | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation All | MTC | Chu | 2017 | NA | 11398 | 5.00e-2 | 3.73e-2 |
Neutrophil | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 6.71e-3 |
Monocyte | Ectopic Fat Traits | Subcutaneous Adipose Tissue Attenuation Men | MTC | Chu | 2017 | NA | 5699 | 1.00e-2 | 3.27e-2 |
Neutrophil (RPS high) | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 5.00e-2 | 2.70e-2 |
Erythroid progenitor cell (RP high) | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 5.00e-2 | 1.69e-2 |
CB CD34+ | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14780 | 1.00e-3 | 3.87e-2 |
Erythroid cell | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7381 | 5.00e-2 | 9.36e-3 |
Erythroid progenitor cell (RP high) | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 1.00e-2 | 3.78e-2 |
Erythroid cell | Ectopic Fat Traits | Subcutaneous Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7399 | 1.00e-3 | 9.98e-3 |
Monocyte | Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Women | MTC | Chu | 2017 | NA | 5729 | 5.00e-2 | 4.14e-2 |
CB CD34+ | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-3 | 1.38e-2 |
B cell | Ectopic Fat Traits | Visceral Adipose Tissue Volume Adjusted For BMI All | MTC | Chu | 2017 | NA | 14863 | 1.00e-3 | 4.80e-2 |
Erythroid progenitor cell (RP high) | Ectopic Fat Traits | Visceral Adipose Tissue Volume Women | MTC | Chu | 2017 | NA | 7431 | 1.00e-2 | 4.40e-2 |
Monocyte | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 9.81e-3 |
Dendritic cell | Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-2 | 1.99e-2 |
Erythroid cell | Facial Shape | Mod1 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.53e-3 |
B cell | Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.88e-2 |
CB CD34+ | Facial Shape | Mod13 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.00e-2 |
CB CD34+ | Facial Shape | Mod17 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 2.22e-2 |
Neutrophil | Facial Shape | Mod18 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.38e-2 |
Neutrophil (RPS high) | Facial Shape | Mod19 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.22e-2 |
Erythroid progenitor cell (RP high) | Facial Shape | Mod21 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.57e-2 |
Erythroid cell | Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.71e-2 |
Erythroid progenitor cell (RP high) | Facial Shape | Mod28 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.71e-2 |
Neutrophil | Facial Shape | Mod29 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.83e-2 |
Dendritic cell | Facial Shape | Mod3 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.61e-2 |
Neutrophil (RPS high) | Facial Shape | Mod34 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.59e-2 |
Dendritic cell | Facial Shape | Mod36 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.61e-2 |
Antigen presenting cell (RPS high) | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.98e-2 |
Antigen presenting cell (RPS high) | Facial Shape | Mod41 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 9.65e-3 |
Antigen presenting cell (RPS high) | Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.38e-2 |
Erythroid progenitor cell (RP high) | Facial Shape | Mod44 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.38e-2 |
B cell | Facial Shape | Mod49 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.99e-2 |
CB CD34+ | Facial Shape | Mod52 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.86e-2 |
Erythroid cell | Facial Shape | Mod53 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.41e-2 |
Erythroid progenitor cell (RP high) | Facial Shape | Mod53 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.33e-2 |
Antigen presenting cell (RPS high) | Facial Shape | Mod54 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.77e-2 |
Antigen presenting cell (RPS high) | Facial Shape | Mod54 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.18e-3 |
Neutrophil (RPS high) | Facial Shape | Mod56 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.49e-2 |
Erythroid cell | Facial Shape | Mod57 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.57e-2 |
Erythroid cell | Facial Shape | Mod58 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.34e-2 |
T cell | Facial Shape | Mod58 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.78e-2 |
Erythroid progenitor cell (RP high) | Facial Shape | Mod58 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 3.78e-2 |
Erythroid cell | Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.59e-2 |
Erythroid cell | Facial Shape | Mod61 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.28e-2 |
Monocyte | Facial Shape | Mod63 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 4.47e-2 |
Erythroid cell | Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 4.28e-2 |
Monocyte | Gestational Weight Gain | Early Gestational Weight Gain Maternal Variants | MTC | Warrington | 2017 | NA | 7704 | 5.00e-2 | 2.00e-2 |
Neutrophil | Gestational Weight Gain | Late Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 7681 | 1.00e-2 | 6.70e-3 |
Neutrophil | Gestational Weight Gain | Total Gestational Weight Gain Offspring Variants | MTC | Warrington | 2017 | NA | 10555 | 1.00e-2 | 4.15e-2 |
Monocyte | Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 4.82e-3 |
Monocyte | Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.95e-2 |
Monocyte | Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 4.14e-3 |
Antigen presenting cell (RPS high) | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 2.82e-2 |
Erythroid progenitor cell (RP high) | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.02e-2 |
Erythroid progenitor cell (RP high) | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 4.91e-2 |
Monocyte | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 2.25e-2 |
B cell | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 4.85e-2 |
Erythroid cell | Glucose Stimulated Insulin Secretion | Corrected Insulin Response | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 1.17e-2 |
Monocyte | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.03e-2 |
Antigen presenting cell (RPS high) | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 4.60e-2 |
B cell | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 1.75e-2 |
B cell | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 4.66e-4 |
CB CD34+ | Glucose Stimulated Insulin Secretion | Disposition Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 2.22e-2 |
Antigen presenting cell (RPS high) | Glucose Stimulated Insulin Secretion | Incremental Insulin At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 3.22e-2 |
Neutrophil | Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 3.92e-2 |
Monocyte | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 5.00e-2 | 2.50e-2 |
Monocyte | Glucose Stimulated Insulin Secretion | Insulin Sensitivity Index | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 1.85e-3 |
Erythroid cell | Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 5.00e-2 | 1.50e-2 |
T cell | Glycemic Traits BMI Corrected | Fasting Glucose Interaction With BMI | MTC | Manning | 2012 | NA | 58074 | 1.00e-2 | 2.15e-2 |
Monocyte | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 4.19e-2 |
CB CD34+ | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 4.19e-2 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 5.00e-2 | 2.62e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-2 | 1.37e-2 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 5.09e-3 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 3.47e-4 |
Erythroid cell | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 4.93e-5 |
Antigen presenting cell (RPS high) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 4.14e-2 |
Antigen presenting cell (RPS high) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 2.45e-2 |
Antigen presenting cell (RPS high) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 2.69e-2 |
Erythroid progenitor cell (RP high) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-3 | 4.14e-2 |
Erythroid progenitor cell (RP high) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-4 | 3.47e-3 |
Erythroid progenitor cell (RP high) | Hemoglobin A1c | Hemoglobin A1c European | MTC | Wheeler | 2017 | NA | 159940 | 1.00e-5 | 8.32e-4 |
Monocyte | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 5.00e-2 | 9.70e-3 |
Monocyte | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 5.14e-3 |
Monocyte | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-3 | 3.29e-2 |
Monocyte | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-5 | 2.87e-2 |
Dendritic cell | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 3.12e-3 |
B cell | Inflammatory Bowel Disease European | Crohn's disease | ETC | Liu | 2015 | 5956 | 14927 | 1.00e-2 | 2.00e-2 |
Monocyte | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 2.78e-4 |
Monocyte | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-2 | 7.87e-4 |
Monocyte | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-3 | 6.52e-4 |
Monocyte | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 1.22e-3 |
Monocyte | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 2.33e-4 |
Dendritic cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 5.00e-2 | 3.56e-2 |
Dendritic cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-2 | 8.79e-3 |
Dendritic cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-3 | 2.34e-3 |
Dendritic cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-4 | 1.22e-3 |
Dendritic cell | Inflammatory Bowel Disease European | Inflammatory Bowel Disease | ETC | Liu | 2015 | 12882 | 21770 | 1.00e-5 | 2.91e-3 |
Monocyte | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 8.03e-6 |
Monocyte | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 2.31e-6 |
Monocyte | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 1.65e-3 |
Monocyte | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 1.58e-3 |
Monocyte | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 5.53e-4 |
Dendritic cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 5.00e-2 | 2.17e-3 |
Dendritic cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-2 | 1.10e-3 |
Dendritic cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-3 | 7.86e-4 |
Dendritic cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 3.64e-5 |
Dendritic cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 1.78e-5 |
B cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-4 | 1.58e-2 |
B cell | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 2.19e-2 |
CB CD34+ | Inflammatory Bowel Disease European | Ulcerative Colitis | ETC | Liu | 2015 | 6968 | 20464 | 1.00e-5 | 9.68e-3 |
Erythroid progenitor cell (RP high) | Insulin Secretion | Insulin Secretion Rate Adjusted For BMI | MTC | Wood | 2017 | NA | 527 | 5.00e-2 | 3.51e-2 |
Erythroid progenitor cell (RP high) | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 4.66e-2 |
Erythroid progenitor cell (RP high) | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 1.30e-2 |
Monocyte | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 1.30e-2 |
Antigen presenting cell (RPS high) | Insulin Sensitivity Index | Model 1 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 2.83e-2 |
Neutrophil | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 4.07e-2 |
Antigen presenting cell (RPS high) | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 5.00e-2 | 2.67e-2 |
Neutrophil (RPS high) | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 4.40e-2 |
Erythroid progenitor cell (RP high) | Insulin Sensitivity Index | Model 3 | MTC | Walford | 2016 | NA | 16753 | 1.00e-2 | 2.22e-2 |
CB CD34+ | Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 4.36e-2 |
Erythroid progenitor cell (RP high) | Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 5.00e-2 | 9.88e-3 |
Erythroid progenitor cell (RP high) | Intracerebral Hemorrhage | All ICH | MTC | Woo | 2014 | 1545 | 1481 | 1.00e-2 | 4.40e-2 |
Erythroid progenitor cell (RP high) | Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 1.00e-2 | 4.15e-2 |
Neutrophil (RPS high) | Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-3 | 5.94e-3 |
CB CD34+ | Ischaemic Stroke | All Stroke | MTC | Traylor | 2012 | 10210 | 12285 | 1.00e-3 | 2.98e-2 |
Erythroid cell | Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 1.00e-2 | 1.57e-2 |
CB CD34+ | Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 3.41e-2 |
CB CD34+ | Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 2.29e-2 |
Neutrophil | Kidney Function | eGFR Decline | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 4.83e-2 |
Erythroid cell | Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 4.25e-2 |
Erythroid progenitor cell (RP high) | Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 4.25e-2 |
Neutrophil | Kidney Function | Rapid Decline | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 2.77e-2 |
Neutrophil | Kidney Function | Serum Creatinine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-4 | 1.86e-2 |
Monocyte | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 5.00e-2 | 1.78e-2 |
Monocyte | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-2 | 3.94e-2 |
Monocyte | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-3 | 3.97e-2 |
Erythroid cell | Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-3 | 3.97e-2 |
Neutrophil | Kidney Function | Serum Creatinine | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-5 | 1.78e-2 |
Erythroid progenitor cell (RP high) | Lean Body Mass | Whole Body Lean Mass | MTC | Zillikens | 2017 | NA | 38292 | 1.00e-2 | 2.98e-2 |
T cell | Leptin | Leptin Adjusted For BMI | MTC | Kilpelainen | 2016 | NA | 32161 | 1.00e-2 | 2.17e-4 |
T cell | Leptin | Leptin Not Adjusted For BMI | ETC | Kilpelainen | 2016 | NA | 32161 | 5.00e-2 | 4.67e-2 |
Monocyte | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 5.00e-2 | 3.89e-2 |
Monocyte | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Activity | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 3.98e-2 |
Monocyte | Lipoprotein Associated Phospholipase A2 | Lipoprotein Associated Phospholipase A2 (LpPLA2) Mass | MTC | Suchindran | 2010 | NA | 6668 | 1.00e-2 | 4.03e-2 |
Monocyte | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 2.74e-2 |
Erythroid progenitor cell (RP high) | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 5.00e-2 | 2.74e-2 |
Erythroid progenitor cell (RP high) | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-2 | 3.63e-2 |
Erythroid progenitor cell (RP high) | Lipoprotein Concentrations | High Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 2.72e-2 |
Neutrophil (RPS high) | Lipoprotein Concentrations | Low Density Lipoprotein | MTC | Kathiresan | 2009 | NA | 19840 | 1.00e-3 | 3.33e-2 |
Monocyte | Loneliness | Loneliness | MTC | Gao | 2017 | NA | 6924 | 5.00e-2 | 4.99e-2 |
Dendritic cell | Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 5.00e-2 | 4.23e-2 |
Dendritic cell | Longevity | Age 85 Or Greater | MTC | Deelen | 2014 | 7729 | 16121 | 1.00e-2 | 7.60e-3 |
Erythroid progenitor cell (RP high) | Longevity | Age 90 Or Greater | MTC | Deelen | 2014 | 5406 | 15112 | 1.00e-3 | 3.87e-2 |
Erythroid cell | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.12e-2 |
B cell | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.12e-2 |
B cell | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 3.86e-3 |
Neutrophil (RPS high) | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.17e-2 |
Dendritic cell | Lymphocyte Subsets | CD3 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.78e-2 |
Monocyte | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.01e-2 |
Monocyte | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 2.55e-3 |
Monocyte | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 7.68e-4 |
Monocyte | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 3.87e-4 |
Monocyte | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 5.70e-3 |
Dendritic cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.01e-2 |
Dendritic cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.06e-3 |
Dendritic cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 5.95e-5 |
Dendritic cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 8.93e-5 |
Dendritic cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.49e-3 |
CB CD34+ | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 2.52e-2 |
B cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 4.20e-4 |
B cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.47e-5 |
B cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 3.87e-4 |
B cell | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 5.70e-3 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 4.53e-2 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 4.62e-2 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD4:CD8 Ratio | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.91e-2 |
Monocyte | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.22e-2 |
Monocyte | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.27e-2 |
Monocyte | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.43e-2 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 3.51e-2 |
Dendritic cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 7.60e-4 |
Dendritic cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.14e-4 |
Dendritic cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 2.13e-4 |
Dendritic cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 6.95e-4 |
B cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 7.60e-4 |
B cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 3.74e-5 |
B cell | Lymphocyte Subsets | CD4 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.43e-2 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 2.83e-2 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 4.84e-3 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 2.50e-2 |
Antigen presenting cell (RPS high) | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.58e-2 |
B cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 5.00e-2 | 4.34e-2 |
B cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 3.81e-2 |
B cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 4.80e-2 |
Monocyte | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 7.81e-3 |
Monocyte | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 3.81e-2 |
Monocyte | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 2.50e-2 |
Monocyte | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.58e-2 |
CB CD34+ | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-2 | 1.66e-2 |
CB CD34+ | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 3.81e-2 |
CB CD34+ | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 4.80e-2 |
Dendritic cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-3 | 1.44e-2 |
Dendritic cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-4 | 2.50e-2 |
Dendritic cell | Lymphocyte Subsets | CD8 Level | MTC | Ferreira | 2010 | NA | 2538 | 1.00e-5 | 1.58e-2 |
Neutrophil | TB LM | Total body lean mass | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-2 | 2.83e-2 |
B cell | TBLH BMD | Total body less head bone mineral density | MTC | Medina-Gomez | 2017 | NA | 10414 | 1.00e-3 | 1.38e-2 |
CB CD34+ | New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 1.00e-2 | 3.34e-3 |
Neutrophil (RPS high) | Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.04e-2 |
Erythroid progenitor cell (RP high) | Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 2.04e-2 |
Erythroid progenitor cell (RP high) | Personality Big5 | Conscientousness | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.00e-3 |
Erythroid cell | Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.13e-2 |
Erythroid cell | Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.91e-2 |
Erythroid progenitor cell (RP high) | Personality Big5 | Extraversion | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 1.91e-2 |
Erythroid progenitor cell (RP high) | Personality Big5 | Neuroticism | MTC | De-Moor | 2012 | NA | 17375 | 1.00e-2 | 3.78e-2 |
Erythroid progenitor cell (RP high) | Pubertal Anthropometrics | Height 10 Year Females | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 2.10e-2 |
Erythroid progenitor cell (RP high) | Pubertal Anthropometrics | Height 10 Year Females And 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 4.31e-2 |
Erythroid progenitor cell (RP high) | Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 5.00e-2 | 3.12e-2 |
Monocyte | Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-2 | 1.66e-2 |
Monocyte | Pubertal Anthropometrics | Height 12 Year Males | MTC | Cousminer | 2013 | NA | 14040 | 1.00e-3 | 3.19e-2 |
B cell | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 4.43e-2 |
Dendritic cell | Pubertal Anthropometrics | Late Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 1.00e-3 | 1.59e-2 |
Neutrophil (RPS high) | Pubertal Anthropometrics | Total Pubertal Height Increase Males | MTC | Cousminer | 2013 | NA | 10799 | 5.00e-2 | 3.14e-2 |
Erythroid cell | Reproductive Behavior | Age First Birth Male | MTC | Barban | 2016 | NA | 48408 | 1.00e-2 | 4.97e-2 |
Erythroid progenitor cell (RP high) | Reproductive Behavior | Number Children Even Born Pooled | MTC | Barban | 2016 | NA | 329139 | 1.00e-4 | 2.58e-2 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 3.15e-2 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 3.16e-3 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 6.53e-4 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 1.78e-3 |
Antigen presenting cell (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 5.25e-3 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 5.00e-2 | 2.25e-2 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 2.22e-2 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 2.90e-3 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 3.04e-4 |
B cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 1.31e-5 |
T cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-2 | 3.39e-2 |
T cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 3.49e-2 |
T cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 4.77e-2 |
Monocyte | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 3.49e-2 |
Monocyte | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 3.30e-2 |
Monocyte | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 1.17e-2 |
Dendritic cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-3 | 2.90e-3 |
Dendritic cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 4.28e-5 |
Dendritic cell | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 1.20e-4 |
Neutrophil (RPS high) | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 3.30e-2 |
CB CD34+ | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-4 | 3.30e-2 |
CB CD34+ | Rheumatoid Arthritis | Rheumatoid Arthritis European | MTC | Okada | 2014 | 14361 | 43923 | 1.00e-5 | 4.77e-2 |
Monocyte | Shoulder Dislocation | Shoulder Dislocation, European Or Latino | MTC | Kim | 2017 | 662 | 82602 | 5.00e-2 | 7.50e-3 |
Neutrophil (RPS high) | Sleep Duration | Oversleeper | MTC | Jones | 2016 | NA | 91306 | 5.00e-2 | 1.62e-2 |
Erythroid progenitor cell (RP high) | Circadian Rhythm | Sleep Chronotype | MTC | Jones | 2016 | NA | 127898 | 1.00e-3 | 4.29e-2 |
Neutrophil (RPS high) | Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 3.81e-2 |
Neutrophil | Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 1.00e-3 | 3.87e-2 |
B cell | Smoking | Cigarettes Per Day | ETC | Furberg | 2010 | NA | 38181 | 1.00e-3 | 1.89e-2 |
Monocyte | Social Deprivation | Household Income One Person Per Household | MTC | Hill | 2016 | NA | 112005 | 1.00e-4 | 4.44e-2 |
Monocyte | Social Deprivation | Townsend Score | MTC | Hill | 2016 | NA | 96900 | 1.00e-3 | 2.95e-2 |
Antigen presenting cell (RPS high) | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 3.59e-2 |
Neutrophil (RPS high) | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 9.46e-3 |
CB CD34+ | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 9.46e-3 |
Erythroid progenitor cell (RP high) | Statin Efficacy | Delta HDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 3.59e-2 |
Antigen presenting cell (RPS high) | Statin Efficacy | Delta HDL With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 4.36e-3 |
Antigen presenting cell (RPS high) | Statin Efficacy | Delta HDL With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.92e-4 |
Erythroid cell | Statin Efficacy | Delta HDL With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 4.97e-2 |
Neutrophil (RPS high) | Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 1.89e-2 |
Neutrophil (RPS high) | Statin Efficacy | Delta LDL With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.99e-3 |
CB CD34+ | Statin Efficacy | Delta LDL With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 4.58e-2 |
Erythroid cell | Statin Efficacy | Delta LDL With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 2.19e-2 |
Monocyte | Statin Efficacy | Delta TC | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 9.06e-3 |
CB CD34+ | Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 3.44e-2 |
Dendritic cell | Statin Efficacy | Delta TC With Statin | MTC | Barber | 2010 | NA | 3928 | 1.00e-3 | 1.35e-2 |
Erythroid cell | Statin Efficacy | Delta TG With Statin | MTC | Barber | 2010 | NA | 3928 | 5.00e-2 | 3.28e-3 |
Monocyte | Tanner Stage | Tanner Stage Males | MTC | Cousminer | 2014 | NA | 3769 | 1.00e-2 | 4.03e-2 |
Neutrophil (RPS high) | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-4 | 1.96e-2 |
Neutrophil (RPS high) | Type 2 Diabetes | Type 2 Diabetes | MTC | Scott | 2017 | 26676 | 132532 | 1.00e-5 | 2.59e-2 |
Erythroid cell | Type 2 Diabetes | Type 2 Diabetes BMI Adjusted | MTC | Scott | 2017 | 26676 | 132532 | 5.00e-2 | 1.40e-2 |
Neutrophil | Waist Format 1 | Hip Circumference Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 4.99e-2 |
CB CD34+ | Waist Format 1 | Waist Circumference European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 3.45e-2 |
Monocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-2 | 1.16e-3 |
Monocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-3 | 8.54e-3 |
Monocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 6.36e-3 |
Monocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 4.54e-4 |
Dendritic cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-4 | 1.81e-2 |
Dendritic cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 2.09e-3 |
Monocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 3.23e-2 |
Monocyte | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 1.89e-2 |
Dendritic cell | Waist Format 1 | Waist Hip Ratio Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 1.89e-2 |
Antigen presenting cell (RPS high) | Waist Format 2 | Hip Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 2.38e-2 |
Antigen presenting cell (RPS high) | Waist Format 2 | Hip Circumference Adjusted For BMI Females European | MTC | Shungin | 2015 | NA | 86570 | 1.00e-5 | 3.76e-2 |
Antigen presenting cell (RPS high) | Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-4 | 1.22e-2 |
Antigen presenting cell (RPS high) | Waist Format 2 | Hip Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-5 | 7.41e-3 |
Monocyte | Waist Format 2 | Waist Circumference Adjusted For BMI European | MTC | Shungin | 2015 | NA | 143480 | 1.00e-5 | 3.19e-2 |
Antigen presenting cell (RPS high) | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-2 | 4.19e-2 |
Antigen presenting cell (RPS high) | Waist Format 2 | Waist Circumference Adjusted For BMI Males European | MTC | Shungin | 2015 | NA | 56910 | 1.00e-3 | 2.06e-3 |
Monocyte | Waist Format 2 | Waist Hip Ratio Males European | MTC | Shungin | 2015 | NA | 56910 | 5.00e-2 | 8.75e-3 |
B cell | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-4 | 2.76e-2 |
B cell | SCZ | Schizophrenia | ETC | Ripke | 2014 | 32405 | 42221+í | 1.00e-5 | 4.29e-2 |
Monocyte | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 2.12e-3 |
Monocyte | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 1.05e-2 |
Monocyte | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 2.87e-3 |
Monocyte | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 3.05e-3 |
Monocyte | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 9.72e-4 |
Antigen presenting cell (RPS high) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 3.28e-3 |
Antigen presenting cell (RPS high) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 1.15e-2 |
Antigen presenting cell (RPS high) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 6.99e-3 |
Antigen presenting cell (RPS high) | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 2.56e-3 |
CB CD34+ | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 4.31e-2 |
Dendritic cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 1.35e-3 |
Dendritic cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 7.88e-5 |
Dendritic cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 1.34e-3 |
Dendritic cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 1.81e-4 |
Dendritic cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 3.68e-5 |
B cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 5.00e-2 | 1.35e-3 |
B cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 6.24e-3 |
B cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 2.59e-4 |
B cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 6.70e-6 |
B cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 8.38e-7 |
T cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-2 | 4.14e-2 |
T cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-3 | 3.81e-2 |
T cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-4 | 1.51e-2 |
T cell | T1D | Type 1 Diabetes | ETC | Bradfield | 2011 | 9934 | 16956 | 1.00e-5 | 3.12e-2 |
Antigen presenting cell (RPS high) | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 5.00e-2 | 3.68e-2 |
Antigen presenting cell (RPS high) | PAN | Pancreatic Cancer | ETC | Amundadottir | 2009 | 1771 | 1805 | 1.00e-2 | 2.95e-2 |
Antigen presenting cell (RPS high) | COL | SSGAC_College | ETC | Rietveld | 2013 | NA | 101069 | 1.00e-4 | 3.23e-2 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 5.00e-2 | 2.61e-3 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 1.82e-2 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.23e-2 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 4.48e-3 |
Erythroid cell | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 2.28e-3 |
Monocyte | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-2 | 4.84e-2 |
Erythroid progenitor cell (RP high) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-3 | 1.88e-2 |
Erythroid progenitor cell (RP high) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 4.48e-3 |
Erythroid progenitor cell (RP high) | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-5 | 5.84e-4 |
CB CD34+ | MCHC | Mean Corpuscular Hemoglobin Concentration | ETC | Astle | 2016 | NA | 173480 | 1.00e-4 | 4.92e-2 |
Monocyte | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 5.00e-2 | 4.08e-2 |
Monocyte | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 2.83e-2 |
Monocyte | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 4.03e-3 |
Monocyte | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 1.08e-2 |
Monocyte | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 5.85e-4 |
Antigen presenting cell (RPS high) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 3.88e-3 |
Antigen presenting cell (RPS high) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 4.03e-3 |
Antigen presenting cell (RPS high) | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 4.65e-3 |
Dendritic cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 1.80e-2 |
Dendritic cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 3.97e-4 |
Dendritic cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 8.47e-6 |
Dendritic cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 8.89e-7 |
B cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-2 | 2.20e-3 |
B cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-3 | 2.71e-5 |
B cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 6.67e-7 |
B cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 2.01e-7 |
T cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-4 | 4.70e-2 |
T cell | PBC | Primary Biliary Cirrhosis | ETC | Cordell | 2015 | 2764 | 10475 | 1.00e-5 | 2.89e-2 |
Neutrophil | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 7.92e-3 |
Neutrophil | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 1.95e-2 |
Monocyte | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 4.16e-2 |
Monocyte | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 7.62e-3 |
Monocyte | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 2.28e-4 |
Monocyte | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 7.19e-5 |
Monocyte | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 5.44e-5 |
B cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 5.00e-2 | 3.08e-2 |
B cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 2.68e-3 |
B cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 2.28e-4 |
B cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 7.19e-5 |
B cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 5.26e-6 |
Dendritic cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-2 | 3.01e-2 |
Dendritic cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-3 | 5.34e-3 |
Dendritic cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 5.20e-4 |
Dendritic cell | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 5.44e-5 |
Antigen presenting cell (RPS high) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-4 | 6.83e-3 |
Antigen presenting cell (RPS high) | SLE | Systemic Lupus Erythematosus | ETC | Bentham | 2015 | 7219 | 15991 | 1.00e-5 | 7.10e-3 |
Monocyte | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 7.93e-3 |
Monocyte | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 3.35e-4 |
Monocyte | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 9.80e-4 |
Monocyte | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 1.45e-3 |
Monocyte | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 8.00e-3 |
Dendritic cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 5.00e-2 | 7.93e-3 |
Dendritic cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 1.19e-2 |
Dendritic cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 2.29e-4 |
Dendritic cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 4.32e-5 |
Dendritic cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 1.08e-5 |
B cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-2 | 2.71e-2 |
B cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-3 | 4.73e-5 |
B cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 6.77e-7 |
B cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 3.23e-5 |
Antigen presenting cell (RPS high) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 6.45e-3 |
Antigen presenting cell (RPS high) | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 3.64e-3 |
T cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-4 | 2.38e-2 |
T cell | T1D CA | Type1Diabetes (Childhood adiposity age < 17) | ETC | Censin | 2017 | 5913 | 8828 | 1.00e-5 | 3.26e-2 |
Neutrophil (RPS high) | EOC | Epithelial Ovarian Cancer | ETC | Phelan | 2017 | 25509 | 40941 | 5.00e-2 | 1.54e-2 |
Erythroid cell | AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 1.00e-2 | 3.51e-2 |
Erythroid progenitor cell (RP high) | AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 1.00e-2 | 1.47e-2 |
Monocyte | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 3.54e-3 |
Monocyte | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 2.82e-3 |
Monocyte | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 1.12e-4 |
Monocyte | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 8.02e-5 |
Monocyte | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 7.57e-6 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 5.00e-2 | 2.42e-3 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-2 | 4.41e-3 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 7.31e-3 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 2.99e-3 |
Antigen presenting cell (RPS high) | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 6.66e-4 |
T cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 1.20e-2 |
T cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 2.99e-3 |
T cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 3.03e-3 |
Dendritic cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 1.42e-3 |
Dendritic cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 3.76e-4 |
Dendritic cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 5.09e-5 |
B cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-3 | 1.91e-2 |
B cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-4 | 2.99e-3 |
B cell | MS | Multiple Sclerosis | ETC | Patsopoulos | 2017 | 14802 | 26703 | 1.00e-5 | 1.25e-4 |
B cell | SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-4 | 4.36e-2 |
B cell | SCZ | Schizophrenia | ETC | Pardinas | 2018 | 40675 | 64643 | 1.00e-5 | 3.00e-2 |
Antigen presenting cell (RPS high) | Glycine level | Glycine levels, both male and female | ETC | Jia | 2019 | NA | 30118 | 5.00e-2 | 2.98e-2 |
Neutrophil (RPS high) | Glycine level | Glycine levels, both male and female | ETC | Jia | 2019 | NA | 30118 | 5.00e-2 | 1.60e-2 |
T cell | Glycine level | Glycine levels, both male and female | ETC | Jia | 2019 | NA | 30118 | 5.00e-2 | 2.98e-2 |
Antigen presenting cell (RPS high) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-2 | 4.22e-2 |
Antigen presenting cell (RPS high) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-3 | 1.40e-2 |
Antigen presenting cell (RPS high) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 4.52e-3 |
Antigen presenting cell (RPS high) | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-5 | 4.55e-3 |
Monocyte | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-4 | 4.80e-2 |
Monocyte | Handedness | Handedness, right-handed vs non-right-handed | ETC | Kovel | 2019 | 293857 | 37180 | 1.00e-5 | 2.03e-2 |
B cell | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 5.00e-2 | 1.83e-2 |
Antigen presenting cell (RPS high) | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-3 | 3.05e-2 |
Antigen presenting cell (RPS high) | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-4 | 1.38e-2 |
Monocyte | Handedness | Handedness, left-handed vs non-left-handed | ETC | Kovel | 2019 | 31856 | 299181 | 1.00e-4 | 4.80e-2 |
Neutrophil (RPS high) | Sleep | Sleep efficiency | ETC | Jones | 2019 | NA | 84810 | 1.00e-5 | 2.22e-2 |
Erythroid cell | Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 3.54e-2 |
Erythroid cell | Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 1.96e-2 |
Antigen presenting cell (RPS high) | Sleep | Sleep number of episodes | ETC | Jones | 2019 | NA | 84810 | 1.00e-4 | 4.15e-2 |
Neutrophil | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 4.36e-2 |
Erythroid cell | Facial attractiveness | Facial attractiveness of females, female raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 1.62e-2 |
Neutrophil | Facial attractiveness | Facial attractiveness of males, female raters | ETC | Hu | 2019 | NA | 1792 | 1.00e-3 | 4.91e-2 |
Monocyte | Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 3.39e-2 |
Erythroid cell | Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 3.39e-2 |
Dendritic cell | Facial attractiveness | Facial attractiveness of females, male raters | ETC | Hu | 2019 | NA | 2062 | 5.00e-2 | 3.66e-3 |
Monocyte | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 5.00e-2 | 4.27e-2 |
Monocyte | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 1.04e-2 |
Monocyte | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 1.91e-4 |
Monocyte | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 2.09e-4 |
Monocyte | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 3.54e-5 |
Dendritic cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-2 | 4.95e-2 |
Dendritic cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-3 | 1.12e-2 |
Dendritic cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 1.24e-3 |
Dendritic cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 3.59e-4 |
Antigen presenting cell (RPS high) | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 2.42e-2 |
Antigen presenting cell (RPS high) | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 2.80e-3 |
B cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-4 | 4.47e-2 |
B cell | Asthma | Asthma, adult-onset | ETC | Ferreira | 2019 | 26582 | 300671 | 1.00e-5 | 7.07e-3 |
Monocyte | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 5.00e-2 | 3.52e-3 |
Monocyte | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 4.46e-4 |
Monocyte | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 1.60e-4 |
Monocyte | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 1.90e-4 |
Monocyte | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 2.93e-4 |
Dendritic cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-2 | 4.58e-3 |
Dendritic cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 5.26e-3 |
Dendritic cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 1.60e-3 |
Dendritic cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 2.93e-4 |
Antigen presenting cell (RPS high) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-3 | 3.28e-2 |
Antigen presenting cell (RPS high) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 2.87e-2 |
Antigen presenting cell (RPS high) | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 2.00e-2 |
B cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-4 | 4.61e-2 |
B cell | Asthma | Asthma, childhood-onset | ETC | Ferreira | 2019 | 13962 | 300671 | 1.00e-5 | 3.49e-2 |
B cell | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-2 | 2.18e-2 |
CB CD34+ | Na/K ratio | Urinary sodium to potassium ratio | ETC | Zanetti | 2019 | NA | 108942 | 1.00e-5 | 3.44e-2 |
Monocyte | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-3 | 3.11e-2 |
CB CD34+ | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-3 | 6.02e-3 |
CB CD34+ | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-4 | 5.21e-3 |
CB CD34+ | K/C ratio | Urinary potassium to creatinine ratio | ETC | Zanetti | 2019 | NA | 218435 | 1.00e-5 | 4.37e-2 |
Neutrophil (RPS high) | Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-3 | 4.56e-3 |
Neutrophil (RPS high) | Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-4 | 2.10e-2 |
Erythroid progenitor cell (RP high) | Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-3 | 2.43e-2 |
Antigen presenting cell (RPS high) | Sleep | Sleep duration, long sleep | ETC | Dashti | 2019 | 34184 | 305742 | 1.00e-4 | 2.10e-2 |
Monocyte | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 5.00e-2 | 1.74e-4 |
Monocyte | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-2 | 3.57e-2 |
Monocyte | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 1.59e-2 |
Monocyte | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 7.10e-3 |
Antigen presenting cell (RPS high) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 3.13e-2 |
Antigen presenting cell (RPS high) | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-4 | 7.10e-3 |
CB CD34+ | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-3 | 3.13e-2 |
Dendritic cell | CTS | Carpal tunnel syndrome | ETC | Wiberg | 2019 | 12312 | 389344 | 1.00e-5 | 1.91e-2 |
Monocyte | MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 5.00e-2 | 4.13e-2 |
Monocyte | MI/CF | Meconium ileus in cystic fibrosis | ETC | Gong | 2019 | 1115 | 5655 | 1.00e-3 | 4.91e-2 |
Erythroid cell | BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 5.00e-2 | 3.22e-2 |
Erythroid progenitor cell (RP high) | BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 5.00e-2 | 4.59e-3 |
Erythroid progenitor cell (RP high) | BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 1.00e-2 | 2.55e-2 |
Erythroid cell | Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 5.00e-2 | 1.49e-2 |
Erythroid cell | Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 1.00e-2 | 3.99e-2 |
Erythroid progenitor cell (RP high) | Obesity | Obese children vs thin adults | ETC | McKay | 2019 | 1471 | 1456 | 5.00e-2 | 4.96e-2 |
Monocyte | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 2.88e-2 |
Monocyte | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 6.20e-3 |
Monocyte | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 1.75e-2 |
Monocyte | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 1.91e-2 |
Monocyte | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 7.16e-3 |
Antigen presenting cell (RPS high) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 1.97e-2 |
Antigen presenting cell (RPS high) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 3.26e-2 |
Neutrophil (RPS high) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 5.63e-3 |
Neutrophil (RPS high) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 1.71e-3 |
Neutrophil (RPS high) | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 1.91e-2 |
T cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 1.33e-2 |
T cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 1.12e-2 |
T cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 1.75e-2 |
T cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 4.38e-2 |
T cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 2.14e-2 |
Erythroid cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 2.88e-2 |
B cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 5.00e-2 | 1.97e-2 |
B cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-2 | 1.71e-3 |
B cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 3.67e-3 |
B cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 2.79e-3 |
B cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 2.14e-3 |
Dendritic cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-3 | 3.67e-3 |
Dendritic cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 7.60e-3 |
Dendritic cell | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-5 | 2.14e-3 |
CB CD34+ | Vitiligo | Vitiligo late onset | ETC | Jin | 2019 | 1467 | 19156 | 1.00e-4 | 4.38e-2 |
Neutrophil | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 5.00e-2 | 2.60e-3 |
Monocyte | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 5.00e-2 | 4.20e-3 |
Monocyte | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-2 | 4.81e-2 |
Monocyte | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 3.13e-2 |
Monocyte | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 2.50e-2 |
Monocyte | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 6.56e-3 |
Neutrophil (RPS high) | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-2 | 4.81e-2 |
Dendritic cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-2 | 2.89e-2 |
Dendritic cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 1.66e-3 |
Dendritic cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 5.36e-4 |
Dendritic cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 1.56e-3 |
B cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-3 | 1.55e-4 |
B cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-4 | 2.18e-3 |
B cell | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 6.56e-3 |
CB CD34+ | Vitiligo | Vitiligo early onset | ETC | Jin | 2019 | 704 | 9031 | 1.00e-5 | 2.37e-2 |
Monocyte | Body fat distribution | Body fat distribution, leg fat ratio, male | ETC | Andersen | 2019 | NA | 116138 | 1.00e-3 | 4.77e-2 |
Monocyte | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-4 | 4.40e-2 |
Monocyte | Osteoarthritis | Osteoarthritis | ETC | Tachmazidou | 2019 | 77052 | 378169 | 1.00e-5 | 2.70e-2 |
Monocyte | Osteoarthritis | Osteoarthritis of the hip or knee | ETC | Tachmazidou | 2019 | 39427 | 378169 | 1.00e-5 | 1.71e-2 |
Neutrophil | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 3.10e-2 |
Neutrophil | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 1.00e-2 | 3.55e-2 |
Dendritic cell | Brain volume | White matter hyperintensity volume | ETC | Traylor | 2019 | NA | 8429 | 5.00e-2 | 3.10e-2 |
Neutrophil (RPS high) | Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-4 | 1.39e-2 |
Neutrophil (RPS high) | Smoking | Smoking initiation ever regular vs never-regular | ETC | Liua | 2019 | NA | 1232091 | 1.00e-5 | 4.21e-2 |
Monocyte | Smoking | Smoking behaviour, cigarettes smoked per day | ETC | Liua | 2019 | NA | 377334 | 1.00e-3 | 4.57e-2 |
Erythroid progenitor cell (RP high) | Smoking | Age of smoking initiation | ETC | Liua | 2019 | NA | 341427 | 5.00e-2 | 1.96e-2 |
Neutrophil | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 3.44e-2 |
Antigen presenting cell (RPS high) | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 1.41e-2 |
Antigen presenting cell (RPS high) | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 7.52e-3 |
Antigen presenting cell (RPS high) | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-3 | 5.07e-3 |
Erythroid cell | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 5.00e-2 | 1.71e-3 |
T cell | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 3.39e-2 |
Dendritic cell | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 1.65e-2 |
B cell | Psoriatic arthritis | Psoriatic arthritis | ETC | Aterido | 2018 | 744 | 1454 | 1.00e-2 | 7.52e-3 |
Dendritic cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-2 | 3.26e-2 |
Dendritic cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 1.21e-3 |
Dendritic cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 2.53e-5 |
Dendritic cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 6.18e-4 |
Monocyte | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-3 | 3.02e-3 |
Monocyte | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 9.65e-3 |
Monocyte | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 2.72e-2 |
B cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-4 | 9.65e-3 |
B cell | Asthma | Asthma, moderate or severe | ETC | Shrine | 2018 | 5414 | 21471 | 1.00e-5 | 8.72e-3 |
Neutrophil (RPS high) | Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.90e-3 |
Erythroid cell | Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 1.03e-2 |
B cell | Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 9.25e-3 |
Dendritic cell | Physical activity | Physical activity, walking duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-3 | 3.72e-2 |
Neutrophil | Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 5.00e-2 | 3.96e-2 |
Antigen presenting cell (RPS high) | Physical activity | Physical activity, moderate intensity activity duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-2 | 3.71e-2 |
Erythroid cell | Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 5.00e-2 | 3.52e-2 |
Erythroid cell | Heart failure | Heart failure | ETC | Aragam | 2018 | 6504 | 387652 | 1.00e-2 | 2.05e-2 |
T cell | Fimbria volume | Fimbria volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.79e-2 |
Antigen presenting cell (RPS high) | Brain volume | Dentate gyrus granule cell layer volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 9.88e-3 |
Antigen presenting cell (RPS high) | Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.28e-2 |
Neutrophil (RPS high) | Hippocampal volume | Hippocampal subfield CA4 volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.71e-2 |
Erythroid cell | Hippocampal volume | Total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 2.30e-2 |
Neutrophil | HATA volume | HATA volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.17e-2 |
Erythroid cell | HATA volume | HATA volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.61e-2 |
Erythroid progenitor cell (RP high) | HATA volume | HATA volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.61e-2 |
Erythroid cell | Brain volume | Dentate gyrus molecular layer volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.38e-2 |
Erythroid cell | Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.62e-2 |
Erythroid cell | Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 1.60e-3 |
Erythroid cell | Hippocampal volume | Hippocampal subfield CA4 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 5.80e-3 |
Erythroid cell | Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 4.97e-2 |
Erythroid cell | Hippocampal volume | Hippocampal subfield CA3 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.79e-2 |
Neutrophil | Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.49e-2 |
Erythroid cell | Hippocampal volume | Hippocampal subfield CA1 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 2.12e-2 |
Erythroid progenitor cell (RP high) | HATA volume | Hippocampal amygdala transition area volume | ETC | Meer | 2018 | NA | 21297 | 5.00e-2 | 3.75e-2 |
Erythroid progenitor cell (RP high) | Hippocampal volume | Hippocampal subfield CA3 volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 2.90e-2 |
Erythroid progenitor cell (RP high) | IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 4.80e-2 |
Neutrophil (RPS high) | ACR | Urinary albumin to creatinine ratio | ETC | Zanetti | 2019 | NA | 218759 | 5.00e-2 | 4.83e-2 |
Erythroid cell | AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 3.34e-2 |
Erythroid progenitor cell (RP high) | AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 5.00e-2 | 3.34e-2 |
Erythroid progenitor cell (RP high) | AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-2 | 2.62e-2 |
CB CD34+ | AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-2 | 4.25e-2 |
CB CD34+ | AUD | Alcohol-Use-Disorder | ETC | Kranzler | 2019 | 34658 | 167346 | 1.00e-3 | 3.12e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 4.53e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-5 | 2.14e-2 |
B cell | Medication use | Medication use (drugs for peptic ulcer and gastro-oesophageal reflux disease) | ETC | Wu Y | 2019 | 53,137 | 79,230 | 1.00e-4 | 1.88e-2 |
B cell | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-4 | 4.76e-2 |
B cell | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-5 | 7.58e-3 |
Dendritic cell | Medication use | Medication use (drugs used in diabetes) | ETC | Wu Y | 2019 | 15,272 | 290,641 | 1.00e-5 | 3.59e-2 |
Monocyte | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 5.00e-2 | 2.00e-3 |
Dendritic cell | Medication use | Medication use (antithrombotic agents) | ETC | Wu Y | 2019 | 67,653 | 85,986 | 1.00e-3 | 4.86e-2 |
Erythroid progenitor cell (RP high) | Medication use | Medication use (vasodilators used in cardiac diseases) | ETC | Wu Y | 2019 | 5,546 | 237,113 | 5.00e-2 | 4.86e-2 |
Monocyte | Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 5.00e-2 | 4.35e-3 |
Monocyte | Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 1.00e-2 | 2.59e-2 |
Monocyte | Medication use | Medication use (beta blocking agents) | ETC | Wu Y | 2019 | 31,700 | 192,324 | 5.00e-2 | 1.69e-2 |
Monocyte | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-2 | 2.54e-2 |
Monocyte | Medication use | Medication use (diuretics) | ETC | Wu Y | 2019 | 34,453 | 194,633 | 1.00e-3 | 1.08e-2 |
Monocyte | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 5.00e-2 | 3.85e-2 |
Monocyte | Medication use | Medication use (calcium channel blockers) | ETC | Wu Y | 2019 | 31,904 | 172,474 | 1.00e-4 | 1.20e-2 |
Monocyte | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 5.00e-2 | 2.29e-2 |
Monocyte | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-3 | 2.01e-2 |
Monocyte | Medication use | Medication use (agents acting on the renin-angiotensin system) | ETC | Wu Y | 2019 | 62,752 | 174,778 | 1.00e-4 | 6.35e-3 |
Monocyte | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 5.00e-2 | 3.95e-2 |
Monocyte | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-2 | 4.25e-2 |
Monocyte | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-3 | 1.99e-2 |
Monocyte | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-4 | 1.75e-2 |
Monocyte | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 4.42e-3 |
Dendritic cell | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-4 | 1.00e-2 |
Dendritic cell | Medication use | Medication use (HMG CoA reductase inhibitors) | ETC | Wu Y | 2019 | 73,475 | 216,910 | 1.00e-5 | 4.42e-3 |
T cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 1.20e-2 |
T cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 7.95e-3 |
T cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 2.02e-3 |
T cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 1.60e-5 |
Dendritic cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-2 | 1.69e-2 |
Dendritic cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 3.99e-4 |
Dendritic cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 4.97e-6 |
Dendritic cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 1.74e-4 |
Antigen presenting cell (RPS high) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-3 | 2.69e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 2.40e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 2.74e-3 |
B cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-4 | 5.87e-3 |
B cell | Medication use | Medication use (thyroid preparations) | ETC | Wu Y | 2019 | 24,832 | 280,750 | 1.00e-5 | 3.64e-4 |
Monocyte | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 5.00e-2 | 4.02e-3 |
Monocyte | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.76e-2 |
Monocyte | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 2.02e-4 |
Monocyte | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 1.12e-3 |
Monocyte | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 4.05e-4 |
Antigen presenting cell (RPS high) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.76e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 3.81e-2 |
Dendritic cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 1.02e-3 |
Dendritic cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 4.23e-6 |
Dendritic cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 2.01e-5 |
Dendritic cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 4.94e-6 |
B cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-2 | 2.22e-3 |
B cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-3 | 5.95e-5 |
B cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-4 | 9.28e-7 |
B cell | Medication use | Medication use (immunosuppressants) | ETC | Wu Y | 2019 | 3,954 | 268,648 | 1.00e-5 | 1.74e-7 |
Neutrophil (RPS high) | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-2 | 3.77e-3 |
Monocyte | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-3 | 1.66e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (anti-inflammatory and antirheumatic products, non-steroids) | ETC | Wu Y | 2019 | 74,150 | 90,370 | 1.00e-5 | 4.38e-2 |
Monocyte | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 5.00e-2 | 4.96e-2 |
Monocyte | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 3.60e-2 |
Monocyte | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 1.17e-2 |
Dendritic cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 2.12e-2 |
Dendritic cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 1.47e-2 |
Dendritic cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-4 | 2.62e-2 |
Dendritic cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 2.24e-3 |
B cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-2 | 6.54e-3 |
B cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-3 | 6.43e-4 |
B cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-4 | 1.81e-3 |
B cell | Medication use | Medication use (drugs affecting bone structure and mineralization) | ETC | Wu Y | 2019 | 7,870 | 207,798 | 1.00e-5 | 4.75e-5 |
B cell | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 5.00e-2 | 1.85e-2 |
B cell | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-3 | 2.92e-2 |
B cell | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-5 | 7.19e-3 |
Monocyte | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-2 | 3.88e-3 |
Monocyte | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-3 | 1.18e-3 |
Monocyte | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-4 | 2.31e-2 |
Monocyte | Medication use | Medication use (opioids) | ETC | Wu Y | 2019 | 22,982 | 55,826 | 1.00e-5 | 7.19e-3 |
Monocyte | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 5.00e-2 | 3.19e-2 |
Monocyte | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-2 | 3.60e-2 |
Dendritic cell | Medication use | Medication use (salicylic acid and derivatives) | ETC | Wu Y | 2019 | 61,583 | 50,427 | 1.00e-3 | 4.86e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 2.76e-2 |
B cell | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-3 | 7.43e-3 |
B cell | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 7.07e-3 |
B cell | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 2.77e-2 |
Monocyte | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-4 | 3.61e-2 |
Monocyte | Medication use | Medication use (anilides) | ETC | Wu Y | 2019 | 83,218 | 96,592 | 1.00e-5 | 3.60e-3 |
Monocyte | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-2 | 5.36e-3 |
Monocyte | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 2.15e-2 |
Monocyte | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 1.41e-2 |
Monocyte | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 3.58e-4 |
Antigen presenting cell (RPS high) | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 3.51e-2 |
Dendritic cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-3 | 7.26e-3 |
Dendritic cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 2.84e-4 |
Dendritic cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 4.11e-5 |
B cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-4 | 2.66e-2 |
B cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 9.70e-4 |
T cell | Medication use | Medication use (adrenergics, inhalants) | ETC | Wu Y | 2019 | 28,880 | 147,565 | 1.00e-5 | 2.82e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 5.00e-2 | 2.80e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 7.43e-3 |
Antigen presenting cell (RPS high) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 4.00e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 3.59e-2 |
Antigen presenting cell (RPS high) | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 3.57e-2 |
Monocyte | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 2.00e-2 |
Monocyte | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 5.21e-3 |
Monocyte | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 8.42e-4 |
Monocyte | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 5.03e-4 |
Dendritic cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 1.24e-2 |
Dendritic cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 1.03e-3 |
Dendritic cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 2.34e-5 |
Dendritic cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 8.29e-6 |
T cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 2.14e-2 |
T cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 2.73e-4 |
T cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 5.11e-3 |
B cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-3 | 5.21e-3 |
B cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-4 | 8.42e-4 |
B cell | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 1.39e-4 |
CB CD34+ | Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-5 | 1.42e-2 |
Monocyte | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 2.84e-2 |
Monocyte | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 2.07e-2 |
Monocyte | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 1.32e-2 |
Monocyte | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 4.38e-2 |
Dendritic cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 5.00e-2 | 1.93e-2 |
Dendritic cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 3.04e-3 |
Dendritic cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 4.16e-6 |
Dendritic cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 3.55e-5 |
Erythroid cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 3.60e-2 |
B cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 8.84e-5 |
B cell | Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-4 | 2.79e-4 |
B cell | Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-2 | 3.97e-2 |
Erythroid cell | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-3 | 1.88e-2 |
Erythroid cell | Varicose veins | Varicose veins | ETC | Shadrina AS | 2019 | 10,861 | 397,594 | 1.00e-5 | 7.41e-3 |
Antigen presenting cell (RPS high) | Renal cell carcinoma | Renal cell carcinoma male | ETC | Laskar RS | 2019 | 3,227 | 4,916 | 5.00e-2 | 2.55e-2 |
Neutrophil | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 2.42e-2 |
Dendritic cell | Periodontal disease | Periodontal disease related phenotype (PCT2) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 2.42e-2 |
Neutrophil | Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 2.76e-2 |
Neutrophil (RPS high) | Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.73e-2 |
Neutrophil (RPS high) | Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 3.51e-2 |
Dendritic cell | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 2.18e-2 |
B cell | Nonalcoholic Liver disease | Non-alcoholic fatty liver disease activity score | ETC | Namjou B | 2019 | NA | 235 | 5.00e-2 | 3.99e-2 |
Neutrophil | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 6.99e-3 |
Antigen presenting cell (RPS high) | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 2,010 | 5,145 | 5.00e-2 | 2.01e-3 |
T cell | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 7,834 | 15,258 | 1.00e-2 | 1.49e-2 |
Erythroid cell | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 2.61e-2 |
Erythroid progenitor cell (RP high) | Stress sensitivity | Stress sensitivity (neuroticism score x major depressive disorder status interaction) | ETC | Arnau-Soler A | 2018 | 9,844 | 20,403 | 1.00e-2 | 2.61e-2 |
Erythroid progenitor cell (RP high) | Multisite chronic pain | Multisite chronic pain | ETC | Johnston KJA | 2019 | NA | 387,649 | 1.00e-2 | 4.36e-2 |
Monocyte | Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 5.00e-2 | 2.35e-2 |
Neutrophil | Longevity | Longevity (age >90th survival percentile) | ETC | Deelen J | 2019 | 11,262 | 25,483 | 1.00e-3 | 3.45e-2 |
Monocyte | Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 5.00e-2 | 3.28e-2 |
B cell | Urinary potassium excretion | Urinary potassium excretion | ETC | Pazoki R | 2019 | NA | 446,230 | 1.00e-5 | 3.44e-2 |
Antigen presenting cell (RPS high) | same-sex sexual behaviour | same-sex sexual behaviour Male | ETC | Ganna A | 2019 | NA | 188,825 | 1.00e-2 | 1.92e-2 |
Antigen presenting cell (RPS high) | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 1.62e-2 |
Antigen presenting cell (RPS high) | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-2 | 1.14e-2 |
CB CD34+ | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 5.00e-2 | 1.62e-2 |
CB CD34+ | same-sex sexual behaviour | same-sex sexual behaviour Female | ETC | Ganna A | 2019 | NA | 220,170 | 1.00e-2 | 1.14e-2 |
Neutrophil (RPS high) | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 4.27e-2 |
CB CD34+ | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 4.27e-2 |
B cell | same-sex sexual behaviour | same-sex sexual behaviour | ETC | Ganna A | 2019 | NA | 408,995 | 1.00e-2 | 2.12e-3 |
Neutrophil | Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 1.00e-2 | 2.52e-2 |
Monocyte | Birth | Post-term birth | ETC | Liu X | 2019 | 7,888 | 60,148 | 5.00e-2 | 2.01e-2 |
Erythroid progenitor cell (RP high) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 5.00e-2 | 4.64e-2 |
B cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-2 | 4.01e-2 |
B cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-3 | 4.30e-2 |
Monocyte | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 5.00e-2 | 1.46e-2 |
Monocyte | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 5.41e-3 |
Monocyte | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 8.47e-3 |
T cell | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 4.48e-2 |
T cell | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 2.98e-2 |
Dendritic cell | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-4 | 2.78e-2 |
Dendritic cell | Asthma | Asthma | ETC | Zhu Z | 2019 | 46,802 | 347,481 | 1.00e-5 | 2.00e-3 |
Monocyte | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 5.00e-2 | 9.34e-6 |
Monocyte | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 1.13e-5 |
Monocyte | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 1.40e-3 |
Monocyte | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 1.25e-4 |
Monocyte | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 9.56e-4 |
Dendritic cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-2 | 3.14e-2 |
Dendritic cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-3 | 9.01e-3 |
Dendritic cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-4 | 7.65e-4 |
Dendritic cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 9.56e-4 |
T cell | Asthma | Asthma (childhood onset) | ETC | Zhu Z | 2019 | 9,676 | 347,481 | 1.00e-5 | 1.57e-2 |
Monocyte | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 5.00e-2 | 5.75e-3 |
Monocyte | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 2.74e-3 |
Monocyte | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-3 | 3.44e-3 |
Monocyte | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-5 | 2.09e-3 |
Dendritic cell | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-3 | 1.59e-2 |
Dendritic cell | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-4 | 2.30e-2 |
Dendritic cell | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-5 | 2.88e-2 |
B cell | Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-5 | 2.88e-2 |
Monocyte | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-2 | 4.81e-2 |
Monocyte | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 1.59e-2 |
Monocyte | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-5 | 4.11e-2 |
Erythroid progenitor cell (RP high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-2 | 9.79e-3 |
Erythroid progenitor cell (RP high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 379,501 | 1.00e-4 | 2.24e-2 |
Neutrophil (RPS high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 1.46e-2 |
Neutrophil (RPS high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-3 | 4.27e-2 |
CB CD34+ | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 4.74e-2 |
Erythroid progenitor cell (RP high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-2 | 2.70e-2 |
Monocyte | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-4 | 1.38e-2 |
Monocyte | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 315,284 | 1.00e-5 | 1.19e-2 |
Erythroid progenitor cell (RP high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-2 | 7.11e-3 |
Erythroid progenitor cell (RP high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-3 | 3.06e-2 |
Erythroid progenitor cell (RP high) | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 3.72e-2 |
Monocyte | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-4 | 7.68e-3 |
Monocyte | Waist to hip ratio | Waist-to-hip ratio adjusted for BMI | ETC | Pulit SL | 2019 | NA | 694,649 | 1.00e-5 | 4.37e-3 |
Antigen presenting cell (RPS high) | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 5.00e-2 | 1.94e-2 |
Antigen presenting cell (RPS high) | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 2.93e-2 |
Antigen presenting cell (RPS high) | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 1.32e-2 |
Monocyte | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-2 | 1.51e-2 |
CB CD34+ | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-3 | 3.57e-2 |
Neutrophil | Body fat percentage | Body fat percentage variance | ETC | Wang H | 2019 | NA | 341,632 | 1.00e-4 | 4.37e-2 |
CB CD34+ | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-2 | 4.99e-2 |
CB CD34+ | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-3 | 4.04e-2 |
CB CD34+ | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-4 | 1.32e-2 |
CB CD34+ | Basal metabolic rate | Basal metabolic rate variance | ETC | Wang H | 2019 | NA | 341,584 | 1.00e-5 | 2.64e-4 |
Monocyte | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-2 | 2.23e-2 |
Monocyte | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-4 | 3.12e-2 |
Antigen presenting cell (RPS high) | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 1.88e-2 |
CB CD34+ | BMI | Body mass index variance | ETC | Wang H | 2019 | NA | 346,393 | 1.00e-5 | 1.88e-2 |
Monocyte | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 5.00e-2 | 5.70e-3 |
Monocyte | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-2 | 4.88e-3 |
Monocyte | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-3 | 1.74e-2 |
CB CD34+ | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-4 | 5.19e-3 |
CB CD34+ | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-5 | 1.32e-2 |
Antigen presenting cell (RPS high) | Waist circumference | Waist circumference variance | ETC | Wang H | 2019 | NA | 347,158 | 1.00e-5 | 3.57e-2 |
CB CD34+ | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-3 | 2.22e-2 |
CB CD34+ | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-4 | 4.82e-3 |
CB CD34+ | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-5 | 2.95e-3 |
Antigen presenting cell (RPS high) | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-4 | 3.13e-2 |
Antigen presenting cell (RPS high) | Hip circumference | Hip circumference variance | ETC | Wang H | 2019 | NA | 346,781 | 1.00e-5 | 2.69e-2 |
Neutrophil (RPS high) | Waist to hip ratio | Waist-hip ratio variance | ETC | Wang H | 2019 | NA | 347,134 | 1.00e-2 | 3.98e-2 |
Monocyte | Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 5.00e-2 | 2.29e-3 |
Monocyte | Height | Height variance | ETC | Wang H | 2019 | NA | 347,086 | 1.00e-2 | 2.72e-2 |
Neutrophil (RPS high) | Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 5.00e-2 | 2.34e-2 |
Erythroid cell | Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 5.00e-2 | 8.49e-3 |
Erythroid progenitor cell (RP high) | Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 5.00e-2 | 1.43e-2 |
CB CD34+ | Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 1.00e-2 | 1.89e-2 |
CB CD34+ | Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 1.00e-3 | 1.49e-3 |
Monocyte | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 5.00e-2 | 2.67e-2 |
B cell | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 5.00e-2 | 2.67e-2 |
T cell | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-2 | 4.40e-2 |
Antigen presenting cell (RPS high) | Lung function | Lung function (FEV1/FVC) variance | ETC | Wang H | 2019 | NA | 316,614 | 1.00e-3 | 2.03e-2 |
Erythroid cell | Heel bone mineral Density | Heel bone mineral density variance | ETC | Wang H | 2019 | NA | 197,261 | 5.00e-2 | 3.91e-2 |
Monocyte | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 2.36e-2 |
Dendritic cell | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 5.00e-2 | 3.68e-2 |
Dendritic cell | Waist to hip ratio | BMI-adjusted waist-hip ratio variance | ETC | Wang H | 2019 | NA | 346,535 | 1.00e-2 | 1.20e-2 |
Antigen presenting cell (RPS high) | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 3.33e-2 |
Antigen presenting cell (RPS high) | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 2.36e-2 |
Dendritic cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 4.90e-2 |
Dendritic cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 1.23e-2 |
Dendritic cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 5.95e-5 |
Dendritic cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 4.49e-6 |
Dendritic cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 5.18e-6 |
B cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 5.00e-2 | 8.93e-3 |
B cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 1.31e-3 |
B cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 1.64e-5 |
B cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 4.49e-6 |
B cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-5 | 5.18e-6 |
T cell | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-2 | 1.23e-2 |
Monocyte | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-3 | 3.05e-2 |
Monocyte | Systemic sclerosis | Systemic sclerosis | ETC | Lopez-Isac E | 2019 | 9,095 | 17,584 | 1.00e-4 | 2.77e-2 |
T cell | Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 2.58e-2 |
Neutrophil | Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 5.00e-2 | 1.03e-2 |
Erythroid progenitor cell (RP high) | Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 5.00e-2 | 3.46e-3 |
CB CD34+ | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 5.00e-2 | 7.19e-3 |
Erythroid cell | Cytokine network | Cytokine network levels (multivariate analysis) | ETC | Nath AP | 2019 | NA | 9,263 | 1.00e-2 | 5.19e-3 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 5.00e-2 | 1.06e-2 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 3.09e-5 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 3.85e-8 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 6.68e-8 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-5 | 1.92e-8 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-2 | 5.79e-4 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 4.70e-5 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 7.60e-7 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-5 | 3.13e-7 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-3 | 1.17e-2 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-4 | 1.35e-2 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (MPO-ANCA positive) | ETC | Lyons PA | 2019 | 159 | 6,688 | 1.00e-5 | 3.22e-3 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 1.08e-2 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 3.97e-2 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 2.58e-4 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 1.19e-5 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-2 | 2.33e-2 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis (ANCA negative) | ETC | Lyons PA | 2019 | 352 | 6,688 | 1.00e-3 | 4.81e-4 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 5.00e-2 | 1.15e-2 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 6.08e-3 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 3.57e-6 |
Dendritic cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 1.87e-7 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-2 | 2.42e-2 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 5.33e-3 |
Monocyte | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 1.59e-2 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-3 | 3.87e-4 |
B cell | Eosinophilic granulomatosis | Eosinophilic granulomatosis with polyangiitis | ETC | Lyons PA | 2019 | 534 | 6,688 | 1.00e-4 | 2.75e-6 |
Monocyte | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 5.00e-2 | 4.04e-2 |
Dendritic cell | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-2 | 1.80e-2 |
Dendritic cell | BMI by age | BMI at 6 weeks old | ETC | Helgeland O | 2019 | NA | 6,450 | 1.00e-3 | 3.23e-2 |
Erythroid progenitor cell (RP high) | BMI by age | BMI at 2 years old | ETC | Helgeland O | 2019 | NA | 4,631 | 5.00e-2 | 4.85e-2 |
Neutrophil (RPS high) | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 2.68e-2 |
Erythroid progenitor cell (RP high) | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 5.00e-2 | 1.70e-3 |
Erythroid progenitor cell (RP high) | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-2 | 2.73e-4 |
Monocyte | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-2 | 3.59e-2 |
Monocyte | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-3 | 9.98e-3 |
Dendritic cell | BMI by age | BMI at 5 years old | ETC | Helgeland O | 2019 | NA | 4,245 | 1.00e-3 | 4.38e-2 |
Antigen presenting cell (RPS high) | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-2 | 4.45e-3 |
Antigen presenting cell (RPS high) | BMI by age | BMI at 7 years old | ETC | Helgeland O | 2019 | NA | 4,629 | 1.00e-3 | 2.98e-2 |
Antigen presenting cell (RPS high) | BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 5.00e-2 | 4.92e-2 |
Antigen presenting cell (RPS high) | BMI by age | BMI at 8 years old | ETC | Helgeland O | 2019 | NA | 3,862 | 1.00e-2 | 2.01e-2 |
Monocyte | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-2 | 2.87e-2 |
Monocyte | Left ventricular | Left ventricular mass to end-diastolic volume ratio | ETC | Aung N | 2019 | NA | 16,884 | 1.00e-3 | 1.32e-2 |
Erythroid progenitor cell (RP high) | Left ventricular | Left ventricular end-systolic volume | ETC | Aung N | 2019 | NA | 16,920 | 5.00e-2 | 1.59e-2 |
Erythroid progenitor cell (RP high) | Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 1.65e-2 |
Dendritic cell | Left ventricular | Left ventricular end-diastolic volume | ETC | Aung N | 2019 | NA | 16,920 | 1.00e-2 | 2.97e-2 |
Erythroid progenitor cell (RP high) | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 5.00e-2 | 5.03e-4 |
Erythroid progenitor cell (RP high) | Optic cup area | Optic cup area | ETC | Bonnemaijer PWM | 2019 | NA | 24,493 | 1.00e-2 | 5.43e-3 |
Erythroid progenitor cell (RP high) | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 2.04e-3 |
Neutrophil | Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 4.19e-2 |
Monocyte | Intraocular pressure | Intraocular pressure | ETC | Bonnemaijer PWM | 2019 | NA | 31,269 | 1.00e-4 | 4.80e-2 |
Neutrophil (RPS high) | Temporale grey matter volume | Right planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,039 | 1.00e-4 | 4.09e-2 |
CB CD34+ | Temporale grey matter volume | Right planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,039 | 1.00e-4 | 4.09e-2 |
Erythroid progenitor cell (RP high) | Temporale asymmetry | Planum temporale asymmetry index | ETC | Carrion-Castillo A | 2020 | NA | 18,049 | 5.00e-2 | 4.48e-2 |
Neutrophil (RPS high) | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 4.02e-2 |
Erythroid cell | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 1.25e-3 |
Erythroid progenitor cell (RP high) | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 5.00e-2 | 4.02e-2 |
CB CD34+ | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 1.00e-2 | 4.84e-2 |
CB CD34+ | Temporale grey matter volume | Left planum temporale grey matter volume | ETC | Carrion-Castillo A | 2020 | NA | 18,037 | 1.00e-3 | 3.22e-2 |
Monocyte | Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 2.40e-2 |
B cell | CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.94e-2 |
Erythroid cell | CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.89e-2 |
B cell | MHC class I | MHC class I polypeptide-related sequence A levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.05e-2 |
Erythroid progenitor cell (RP high) | CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.94e-2 |
Erythroid progenitor cell (RP high) | Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.85e-2 |
Monocyte | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.65e-2 |
Monocyte | Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 8.77e-3 |
Monocyte | Metabolic syndrome | Metabolic syndrome | ETC | Lind L | 2019 | NA | 291,107 | 5.00e-2 | 4.99e-2 |
Neutrophil (RPS high) | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 5.00e-2 | 3.64e-2 |
B cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 5.00e-2 | 8.57e-3 |
B cell | Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Casanova F | 2019 | NA | 437,027 | 1.00e-2 | 1.55e-2 |
Erythroid cell | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 5.00e-2 | 1.62e-3 |
Dendritic cell | Steroid sensitive nephrotic syndrome | Childhood steroid-sensitive nephrotic syndrome | ETC | Debiec H | 2018 | 132 | 2,000 | 1.00e-2 | 1.42e-2 |
Antigen presenting cell (RPS high) | Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 2.45e-2 |
Monocyte | Parental lifespan | Parental lifespan | ETC | Timmers PR | 2019 | NA | 500,193 | 5.00e-2 | 2.15e-2 |
Erythroid cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 2.07e-3 |
Erythroid cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-2 | 3.32e-2 |
Erythroid cell | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 3.15e-2 |
Erythroid progenitor cell (RP high) | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 5.00e-2 | 2.07e-3 |
Erythroid progenitor cell (RP high) | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-2 | 3.32e-2 |
Erythroid progenitor cell (RP high) | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-3 | 3.15e-2 |
Erythroid progenitor cell (RP high) | Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 1.93e-2 |
T cell | COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 1.00e-2 | 4.62e-2 |
Erythroid cell | COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 1.00e-2 | 1.81e-2 |
Erythroid progenitor cell (RP high) | COVID-19 Host Genetics | predicted covid from self-reported symptoms vs. predicted or self-reported non-covid (EA) | ETC | covid19hg | 2020 | 1865 | 29174 | 1.00e-2 | 4.62e-2 |
Monocyte | COVID-19 | Severe COVID-19 infection with respiratory failure (analysis I) | ETC | Ellinghaus D | 2020 | 1610 | 2205 | 1.00e-2 | 6.43e-4 |
Monocyte | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 5.00e-2 | 1.57e-2 |
Monocyte | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-3 | 5.06e-3 |
Monocyte | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 5.73e-5 |
Monocyte | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 7.18e-5 |
B cell | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-4 | 2.89e-2 |
B cell | Alzheimer's disease (late onset) | late-onset Alzheimers disease | ETC | Kunkle BW | 2019 | 21982 | 41944 | 1.00e-5 | 2.62e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.